Anti-Obesity Drugs Market Size, Share and Forecast Trends - Growth Analysis and Outlook Report (2026-2035)

Read more about this report - Request a Free Sample

Anti-Obesity Drugs Market Overview

Anti-obesity drugs are increasingly gaining attention as pharmacological support for weight management alongside lifestyle modification and clinical intervention. They play a growing role in improving metabolic health outcomes and addressing obesity-related complications across diverse patient groups. The market is poised to reach USD 417.17 Billion by 2035, driven by rising obesity prevalence, increasing adoption of GLP-1 agonists, and continuous innovation in therapeutic pipelines. The expanding healthcare awareness, improved access to treatment, and a shift toward long-term pharmacological weight management are further supporting demand. The growing investments by pharmaceutical companies and advancements in next-generation therapies are expected to strengthen market expansion.

Anti-Obesity Drugs Market Segmentation

Anti-Obesity Drugs Market Growth Analysis and Key Influencers

Anti-Obesity Drugs Market Dynamics

The following section outlines the key factors influencing the growth of the market, including major drivers, restraints, and emerging opportunities.

Anti-Obesity Drugs Market Growth Drivers

Rising Obesity Prevalence Expectedto Drive the Market Expansion

Increasing prevalence of obesity in India is a major driver for the anti-obesity drugs market growth and value expansion. According to the Press Information Bureau India, recent data indicates that 24% of women and 23% of men are overweight or obese, while 6.4% of women and 4.0% of men in the age group of 15 to 49 years are obese. This increasing burden of obesity is contributing to higher clinical attention and expanding demand for pharmacological weight management therapies, thereby supporting sustained market growth.

Anti-Obesity Drugs Market Restraints

High Cost of GLP-1 Therapies Restrains the Growth of the Market

High treatment costs of advanced anti-obesity therapies represent a major restraint in the market. According to the National Academy of Medicine, GLP-1 drugs can exceed USD 1,000 per month, and even after insurance coverage and discount programs, they remain financially burdensome for many patients. This persistent affordability challenge restricts patient access and limits market expansion despite increasing clinical demand worldwide.

Anti-Obesity Drugs Market Opportunities

Expansion of GLP-1 Therapeutics in Regulated Markets Creating Growth Opportunity

The growing adoption of GLP-1 therapies for diabetes and obesity presents a key market opportunity driven by rising demand for effective metabolic disorder and weight management treatments. For example, in February 2025, Biocon Limited launched its GLP-1 peptide Liraglutide in the United Kingdom after Medicines and Healthcare Products Regulatory Agency approval, entering a major regulated market with affordable generic formulations. According to Biocon Limited press release, this expansion indicates improving accessibility and future penetration across Europe, strengthening growth prospects for GLP-1-based therapies.

Anti-Obesity Drugs Market Trends

The market is witnessing several trends including policy-driven access expansion, GLP-1 adoption, oral obesity drugs.

Rising Strategic Partnerships in Obesity Therapies are Likely to Accelerate the Market Value

Increasing collaborations between pharmaceutical companies and government bodies are improving access to advanced anti-obesity therapies. For instance, in November 2025, Eli Lilly and the U.S. government reached an agreement to expand access to Zepbound and the investigational oral drug orforglipron, reducing monthly treatment costs for Medicare beneficiaries. This initiative enhances affordability and broadens patient reach, thereby supporting sustained growth in the market.

Anti-Obesity Drugs Market Share

Semaglutide Segment are Set to Lead the Market by Drug Type

The market is segmented by drug type into semaglutide, tirzepatide, liraglutide, phentermine/ topiramate, naltrexone/ bupropion, orlistat, phentermine, gelesis100, and others. Among these, semaglutide is expected to lead due to its superior weight reduction outcomes, strong GLP-1 receptor agonist profile, and increasing clinical adoption. The rising obesity prevalence and preference for injectable incretin-based therapies further support demand. For example, in April 2026, the Medicines and Healthcare products Regulatory Agency (MHRA) approved a single-dose 7.2 mg semaglutide pen for adult obesity management, enhancing accessibility and treatment adherence. This advancement is expected to strengthen the segment growth significantly.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Read more about this report - Request a Free Sample

Anti-Obesity Drugs Market Analysis by Region

The regions included in the report are United States, United Kingdom, Germany, France, Italy, Spain, Japan, and India, with the United States emerging as the leading region. In the United States, the market is driven by strong regulatory oversight and high adoption of GLP-1 therapies; for instance, in February 2026, the Food and Drug Administration issued safety concerns regarding unapproved and compounded semaglutide and tirzepatide, highlighting risks of counterfeit products, dosing errors, and quality issues. This regulatory scrutiny reinforces patient safety measures and supports demand for approved therapies, strengthening market growth compared with other regions.

Leading Players in the Anti-Obesity Drugs Market

Key Questions Answered in the Anti-Obesity Drugs Market Report

• What was the anti-obesity drugs market value in 2025?
• What is the anti-obesity drugs market forecast outlook for 2026-2035?
• What major factors aid the demand for the anti-obesity drugs market?
• How has the market performed so far, and how is it anticipated to perform in the coming years?
• What are the market's major drivers, opportunities, and restraints?
• What are the major anti-obesity drugs market trends?
• Which drug type is expected to dominate the market segment?
• Which drug class is projected to lead the market segment?
• Which prescription type is anticipated to drive the market segment?
• Which route of administration is likely to dominate the market segment?
• Which age group is expected to dominate the market segment?
• Which distribution channel is projected to lead the market segment?
• Who are the key players in the anti-obesity drugs market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?